News & Media

Take a look inside our world

Press Releases

Teva Releases Q2 2025 Aide Memoire

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 3...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 20

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (frema...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezum

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maxi

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Sett...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperi...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone)

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovat...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation a

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Access to Medicine Biologics Biosimilars Caregivers Environment Generic Medicines Global Operations Immunology Innovation Leadership Inclusion & Diversity Neuroscience Our People Patient Focus Quality Research & Development Respiratory Sustainability Wellbeing Working at Teva

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

A Passport to Career Development: A Journey with Teva's R&D Teams

A Passport to Career Development: A Journey with Teva's R&D Teams

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Migraine at Work: How it Impacts Us All

Migraine at Work: How it Impacts Us All

What are Biologics and Biosimilars?

What are Biologics and Biosimilars?

Medical Specialists We All Need but Never See: Safety Physicians

Medical Specialists We All Need but Never See: Safety Physicians

3 Trends I’m Watching in Sustainability

3 Trends I’m Watching in Sustainability
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more